EN zh-TW

newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

business / news / / Markets Insider

David Dai from UBS maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$31.00.

UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals with a A$31.00 target.

KEY POINTS
COMPANIES
Read the full story on Markets Insider → →
Share X LinkedIn

Summarized by Newsio from Markets Insider. How we summarize →

RELATED 03
genai · news · 12h 211

Meta Business Agent is an AI-powered assistant designed to help businesses automate customer support, sales, scheduling and other operational tasks.

  • Meta launched Meta Business Agent, an AI assistant to automate sales, support, and scheduling tasks.
  • Meta Business Agent can integrate with external enterprise software to perform actions using business data.
The Economic Times →
business · news · 4h 140

The European Commission is investigating the $111 billion Paramount-WBD deal.

  • The EU is probing $24 billion in Middle Eastern funding of the Paramount-WBD merger under new subsidy rules.
  • Paramount disclosed Gulf States will own about 38.5% equity in the merged company but lack voting rights.
Variety →
business · news · 5h 136

U.S. entertainment giant sought EU approval under its Foreign SubsidiesRegulation.

  • Paramount Skydance Corp's $110 billion takeover of Warner Bros Discovery is under EU subsidy scrutiny.
  • The deal is backed by Saudi PIF, Abu Dhabi's L'imad Holding, and Qatar Investment Authority.
The Star →